A transcriptionally and functionally distinct pd-1+ cd8+ t cell pool with predictive potential in non-small-cell lung cancer treated with pd-1 blockade

Nature Medicine

Volumn 24, Issue 7, 2018, Pages 994-1004

  Thommen, Daniela S ^a,b   Koelzer, Viktor H ^c,d   Herzig, Petra ^a   Roller, Andreas ^e   Trefny, Marcel ^a   Dimeloe, Sarah ^a   Kiialainen, Anna ^e   Hanhart, Jonathan ^c   Schill, Catherine ^c   Hess, Christoph ^a   Prince, Spasenija Savic ^f   Wiese, Mark ^a   Lardinois, Didier ^a   Ho, Ping Chih ^g   Klein, Christian ^h   Karanikas, Vaios ^h   Mertz, Kirsten D ^c   Schumacher, Ton N ^b   Zippelius, Alfred ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Kantonsspital Liestal   (Switzerland)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

^h Roche Pharmaceutical Research and Early Development   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GILVETMAB; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 2; MESSENGER RNA; RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR; CXCL13 CHEMOKINE; GLUCOSE; PROGRAMMED DEATH 1 RECEPTOR;

ADENOCARCINOMA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE REGULATION; CELL POPULATION; COHORT ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXHAUSTION; HUMAN; IMMUNOCOMPETENT CELL; NON SMALL CELL LUNG CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TERTIARY LYMPHOID STRUCTURE; VIRUS INFECTION; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; LIPID METABOLISM; LUNG TUMOR; METABOLISM; MITOCHONDRION; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE; ULTRASTRUCTURE;

CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CXCL13; CHRONIC DISEASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; HUMANS; LIPID METABOLISM; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MITOCHONDRIA; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC; VIRUS DISEASES;

EID: 85048343664     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/s41591-018-0057-z     Document Type: Article

References (56)

1. Castle, J. C. et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72, 1081–1091 (2012).
2. Heemskerk, B., Kvistborg, P. & Schumacher, T. N. The cancer antigenome. EMBO J. 32, 194–203 (2013).
3. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
4. Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
5. Schietinger, A. & Greenberg, P. D. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35, 51–60 (2014).
6. + T cells in metastases from melanoma patients. J. Clin. Invest. 121, 2350–2360 (2011).
7. Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205–2213 (1998).
8. Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).
9. Wherry, E. J. et al. Molecular signature of CD8+T cell exhaustion during chronic viral infection. Immunity 27, 670–684 (2007).
10. Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006).
11. Trautmann, L. et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12, 1198–1202 (2006).
12. Golden-Mason, L. et al. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81, 9249–9258 (2007).
13. Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114, 1537–1544 (2009).
14. Thommen, D. S. et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. CancerImmunol. Res. 3, 1344–1355 (2015).
15. Schreiner, J. et al. Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. Oncoimmunology 5, e1062969 (2015).
16. Zippelius, A. et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 64, 2865–2873 (2004).
17. Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by αPD-L1 blockade. Proc. Natl Acad. Sci. USA 105, 15016–15021 (2008).
18. + T cells cooperate to contain chronic viral infection. Science 338, 1220–1225 (2012).
19. Grosso, J. F. et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182, 6659–6669 (2009).
20. Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).
21. + T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res. 77, 6353–6364 (2017).
22. Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
23. Wolfl, M. et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110, 201–210 (2007).
24. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246–2259 (2014).
25. Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016).
26. Inozume, T. et al. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J. Immunother. 33, 956–964 (2010).
27. Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342–1356.e1316 (2017).
28. Henson, S. M. et al. KLRG1 signaling induces defective Akt (Ser473) phosphorylation and proliferative dysfunction of highly differentiated CD8+ T cells. Blood 113, 6619–6628 (2009).
29. + T cell dysfunction during chronic infection. Immunity 40, 289–302 (2014).
30. Schietinger, A. et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 45, 389–401 (2016).
31. Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
32. Singer, M. et al. A distinct gene module for dysfunction uncoupled from activation in tumor-infiltrating T cells. Cell 166, 1500–1511.e1509 (2016).
33. Gupta, P. K. et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 11, e1005177 (2015).
34. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 16, 1147–1151 (2010).
35. Doering, T. A. et al. Network analysis reveals centrally connected genes and pathways involved in CD8+T cell exhaustion versus memory. Immunity 37, 1130–1144 (2012).
36. Scharping, N. E. et al. The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction. Immunity 45, 701–703 (2016).
37. Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).
38. Ho, P. C. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162, 1217–1228 (2015).
39. Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225–236 (2013).
40. MacIver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259–283 (2013).
41. van der Windt, G. J. et al. CD8 memory T cells have a bioenergetic advantage that underlies their rapid recall ability. Proc. Natl Acad. Sci. USA 110, 14336–14341 (2013).
42. Schurich, A. et al. Distinct metabolic requirements of exhausted and functional virus-specific CD8 T cells in the same host. Cell Rep. 16, 1243–1252 (2016).
43. Sukumar, M. et al. Inhibiting glycolytic metabolism enhances CD8+T cell memory and antitumor function. J. Clin. Invest. 123, 4479–4488 (2013).
44. Wang, Y. et al. Autocrine complement inhibits IL10-dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Discov. 6, 1022–1035 (2016).
45. + T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).
46. + T cells curtail chronic viral infection. Nature 537, 412–428 (2016).
47. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309–314 (2000).
48. Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).
49. Gu-Trantien, C. et al. CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer. JCI Insight 2, 91487 (2017).
50. Gunnlaugsdottir, B., Maggadottir, S. M. & Ludviksson, B. R. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+and CD8+naïve human T-cells. Int. Immunol. 17, 35–44 (2005).
51. Allen, C. D. et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5, 943–952 (2004).
52. Wu, T. D., Reeder, J., Lawrence, M., Becker, G. & Brauer, M. J. GMAP and GSNAP for genomic sequence alignment: enhancements to speed, accuracy, and functionality. Methods Mol. Biol. 1418, 283–334 (2016).
53. Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621–628 (2008).
54. Becker, R. A., Chambers, J. M. & Wilks, A. R. The New S Language (Wadsworth & Brooks/Cole, Monterey, CA, USA, 1988).
55. Falcon, S. & Gentleman, R. Using GOstats to test gene lists for GO term association. Bioinformatics 23, 257–258 (2007).
56. Nazarov, V. I. et al. tcR: an R package for T cell receptor repertoire advanced data analysis. BMC Bioinformatics 16, 175 (2015).